Operator of a consumer platform providing prescription drug price comparisons, discount coupons and telehealth services.
Operator of a consumer platform providing prescription drug price comparisons, discount coupons and telehealth services.
When a customer uses a coupon at the pharmacy, the pharmacy benefit manager that processes the claim pays GoodRx a fee, so its main income is per prescription filled, not what the consumer pays. Subscriptions and drug-maker advertising and savings programmes add smaller streams.
Moat: narrow (network effects, brand, data). Large consumer brand and pharmacy network create a two-sided marketplace effect, though PBMs can undercut pricing.
Headquarters: Santa Monica, California · Founded: 2011 · Employees: 697
Size GoodRx (GDRX) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.15B, the 2148th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.36 on 18 Nov 2026.
Performance Over six months the shares gained 33.3%, against +11.9% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 1.8% over the last twelve months (peer median +6.8%); the operating margin is 12.0% (peer median 6.2%).
Valuation It trades at 10.6× forward earnings against a peer median of 25.3× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.5 points below its cost of capital (10.9% WACC).
Short interest Short interest is 3.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $785M | $797M | $792M | $750M | $767M |
| Revenue growth | — | +1% | +6% | -2% | — |
| Gross profit | $625M | $654M | $675M | $580M | $648M |
| EBITDA | $183M | $192M | $159M | $163M | $94.7M |
| Net income | $16.2M | $30.4M | $16.4M | -$8.87M | -$32.8M |
| Free cash flow | $197M | $164M | $183M | $137M | $143M |
| Capital expenditure | $69.9M | $74.0M | $70.3M | $55.8M | $55.2M |
| Total debt | $539M | $543M | $543M | $711M | $717M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| GoodRx GDRX | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% |
| Amazon AMZN | $2.90T | +1% | +15% | 13% | 27.1× | n/a |
| UnitedHealth UNH | $314B | -8% | +3% | 5% | 15.4× | 3.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GDRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | +2.2% | 7th lowest of 21 |
| 6-month return | +33.3% | +11.9% | 5th highest of 21 |
| Distance from 52-week high | -13.6% | -24.0% | 7th highest of 21 |
| Revenue growth (TTM) | -1.8% | +6.8% | 6th lowest of 21 |
| Operating margin | 12.0% | 6.2% | 5th highest of 21 |
| Forward P/E | 10.6× | 25.3× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 6.3% | 8.5% | 7th least demanding of 17 |
| Growth delivered (Del g) | +7.7% | +10.7% | 6th lowest of 17 |
| Hurdle (Req g minus delivered) | -1.4 pp | -0.4 pp | 8th least demanding of 17 |
| ROIC minus cost of capital | -2.5 pp | -2.4 pp | 10th highest of 19 |
| EV / EBITDA | 7.6× | 9.6× | 6th cheapest of 16 |
| Net debt / EBITDA | 1.3× | 1.4× | 9th least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Regis Healthcare REG.AX | Australia | $962M | -28% | +17% | 4% | 25.3× | 13.3% | +14.4% |
| BML 4694.T | Japan | $932M | +12% | +4% | 7% | 19.8× | -9.0% | +1.6% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Thyrocare Technologies THYROCARE.NS | India | $858M | +7% | +22% | 26% | 36.0× | 28.5% | +10.9% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Terveystalo Oy TTALO.HE | Finland | $832M | -26% | -8% | 8% | 10.7× | -5.1% | +5.3% |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |